The need to trace pharmaceutical products for economic reasons
Traceability of pharmaceutical products in hospitals
Article REF: TR330 V2
The need to trace pharmaceutical products for economic reasons
Traceability of pharmaceutical products in hospitals

Author : Luc ROZENBAUM

Publication date: November 10, 2013 | Lire en français

Logo Techniques de l'Ingenieur You do not have access to this resource.
Request your free trial access! Free trial

Already subscribed?

2. The need to trace pharmaceutical products for economic reasons

The revenue generated by healthcare establishments depends on the medical activity carried out. Tarification à l'activité (T2A) (activity-based pricing) replaces the dotation globale des établissements de santé. Homogeneous groups of hospital stays (GHS) are now described, and funding is based on the number of procedures performed.

However, certain drugs and implantable medical devices (e.g. orthopedic prostheses, pacemakers) are reimbursed by compulsory health insurance schemes in addition to the GHS; these are referred to as non-GHS. To be reimbursed by the hospital, they must be fully traceable, from prescription to administration, and their proper use must be assessed in line with official indications and recommendations. A multi-year contract is signed between each healthcare establishment and the regional hospitalization agency on which the establishment depends,...

You do not have access to this resource.
Logo Techniques de l'Ingenieur

Exclusive to subscribers. 97% yet to be discovered!

You do not have access to this resource. Click here to request your free trial access!

Already subscribed?


Ongoing reading
The need to trace pharmaceutical products for economic reasons

Article included in this offer

"Traceability"

( 56 articles )

Complete knowledge base

Updated and enriched with articles validated by our scientific committees

Services

A set of exclusive tools to complement the resources

View offer details
Contact us